Full Breakdown
Breakthrough Blood Test Predicts Severe Liver Disease Risk
9/30/2025, 2:31:34 AM
Introduction to the CORE Model
Researchers at Karolinska Institutet in Sweden have developed a new blood test, known as the CORE model (Cirrhosis Outcome Risk Estimator), which can predict the risk of severe liver diseases, including cirrhosis and liver cancer, up to ten years before symptoms manifest. The study, published in The BMJ, highlights the test's potential to revolutionize early diagnosis and intervention in primary care settings, where initial medical consultations typically occur.
How the CORE Model Works
The CORE model utilizes routine health data, specifically three liver enzyme markers: aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT), along with demographic factors such as age and sex. By analyzing these parameters through advanced statistical methods, the model was trained on health data from over 480,000 individuals in Stockholm, followed for up to 30 years. The model demonstrated an impressive accuracy rate of 88% in distinguishing individuals who would develop severe liver disease from those who would not.
Significance of Early Detection
Liver diseases are increasingly prevalent and often progress silently, leading to poor prognoses when diagnosed late. The CORE model addresses this critical gap by providing a simple, cost-effective tool for early detection. With drug treatments available for high-risk patients, timely identification through the CORE model could facilitate early intervention and lifestyle modifications, potentially saving lives and reducing healthcare burdens.
Validation and Comparative Performance
The CORE model has shown superior predictive performance compared to existing tools, notably the FIB-4 index, which has limitations in unselected populations. Validation studies conducted in Finland and the United Kingdom confirmed the model's high predictive accuracy across diverse demographics. However, further research is needed to assess its effectiveness in specific high-risk groups, such as individuals with type 2 diabetes or obesity.
Official Statements & Responses
Rickard Strandberg, a researcher involved in the study, emphasized the importance of early detection, stating, “Liver diseases are becoming increasingly common, and if diagnosed too late, the prognosis is extremely unfavorable.” Hannes Hagström, the principal investigator, noted that the CORE model represents a significant step toward mass screening for liver disease in primary care settings.
Criticism & Opposition
While the CORE model shows promise, some experts have raised concerns regarding the model's reliance on older health data, with the most recent lab values dating back to 1996. Additionally, the model's applicability in populations outside Western Europe remains to be fully established, necessitating further validation in diverse settings.
What's Next for the CORE Model
The researchers aim to integrate the CORE model into electronic health record systems to facilitate routine clinical use. An online calculator is already available for healthcare professionals to estimate a patient's 10-year risk of developing severe liver disease. As liver disease continues to be a growing concern globally, the CORE model could play a pivotal role in transforming liver health management.
Verbatim Quotes
- “Our method can predict the risk of severe liver disease within 10 years and is based on three simple routine blood tests.” — Rickard Strandberg, Researcher, Karolinska Institutet
- “This is an important step towards mass screening of liver disease at an early stage,” — Hannes Hagström, Principal Investigator, Karolinska Institutet
- “CORE could become an important tool to save the lives and health of thousands of patients.” — Hannes Hagström, Principal Investigator, Karolinska Institutet
